Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELOXX PHARMACEUTICALS, INC.

(ELOX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

11/17/2021 | 07:00am EST

Eloxx Pharmaceuticals, Inc. announced positive topline results from the monotherapy arms of its Phase 2 clinical trial of ELX-02 in Class 1 cystic fibrosis (CF) patients with at least one G542X nonsense allele mutation. ELX-02 was well tolerated and achieved a statistically significant 5.4mmol/L reduction in sweat chloride in patients at the1.5mg/kg/day dose. The intra-patient dose escalation stage of the trial has successfully identified 1.5 mg/kg/day as the dose for further development. Based on the statistically significant monotherapy results observed at the 1.5mg/kg/day dose, planning for the advancement of ELX-02 into Phase 3 clinical development has started. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ELX-02. In addition, ELX-02 has also been granted Orphan Drug Designation for the treatment of CF patients with nonsense mutations by the FDA and orphan medicinal product designation by the European Medicines Agency.


ę S&P Capital IQ 2021
All news about ELOXX PHARMACEUTICALS, INC.
01/24B. Riley Lowers Eloxx Pharmaceuticals' Price Target to $3 from $5 After Revising Cost C..
MT
01/05ELOXX PHARMACEUTICALS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listin..
AQ
2021Oppenheimer Initiates Coverage on Eloxx Pharmaceuticals With Outperform Rating, $4 Pric..
MT
2021HC Wainwright Adjusts Eloxx Pharmaceuticals' Price Target to $1 From $2, Keeps Neutral ..
MT
2021ELOXX PHARMACEUTICALS : Topline ELX-02 Phase 2 Results Call and Webcast
PU
2021Eloxx Pharmaceuticals' Mid-Stage Cystic Fibrosis Trial Meets Key Secondary Endpoint, Sa..
MT
2021ELOXX PHARMACEUTICALS : Reports Positive Topline Results from Monotherapy Arms of Phase 2 ..
PU
2021ELOXX PHARMACEUTICALS, INC. : Regulation FD Disclosure, Other Events, Financial Statements..
AQ
2021Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2..
AQ
2021Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2..
CI
More news
Analyst Recommendations on ELOXX PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -64,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,55x
Yield 2021 -
Capitalization 44,9 M 44,9 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 25
Free-Float -
Chart ELOXX PHARMACEUTICALS, INC.
Duration : Period :
Eloxx Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELOXX PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 0,52 $
Average target price 3,00 $
Spread / Average Target 477%
EPS Revisions
Managers and Directors
Sumit Aggarwal President, Chief Executive Officer & Director
Daniel E. Geffken Chief Financial & Accounting Officer
Tomer Kariv Chairman
Vijay Modur Head-Research & Development
Ali Hariri Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ELOXX PHARMACEUTICALS, INC.-26.37%45
MODERNA, INC.-39.94%61 847
LONZA GROUP AG-20.30%49 060
IQVIA HOLDINGS INC.-16.27%45 129
SEAGEN INC.-19.08%22 875
ICON PUBLIC LIMITED COMPANY-19.15%20 381